The CorCinch-HF pivotal study is a prospective, randomized, open-label, multicenter, international, clinical safety and efficacy investigation of the AccuCinch System, which is designed to enroll 400 ...

Six-month safety and effectiveness data for the 250 randomized patients to support PMA submission to FDA; enrollment to continue to 400 The AccuCinch System is an investigational device designed to ...

Pivotal Trial to Evaluate Safety and Efficacy of AccuCinch® Ventricular Restoration System in Heart Failure Patients with Reduced Ejection Fraction SANTA CLARA, Calif.--(BUSINESS WIRE)--Ancora Heart, ...

The CAMC Clinical Trials Center is enrolling patients in a clinical trial to evaluate a new treatment option for heart failure patients. The CORCINCH-HF Study is evaluating the safety and efficacy of ...

SANTA CLARA, Calif., October 23, 2025--(BUSINESS WIRE)--Ancora Heart, Inc., a medical device company developing a transcatheter device-based therapy to address heart failure (HF), today announced that ...

Study coordinators who want to add a study should Submit a Clinical Trial. For more information or to remove a study, please email pa-webteam@bcm.edu. MyChart is a ...

Ancora Heart, a private company focused on the treatment of heart failure, has raised an $80 million equity financing. The Santa Clara, CA-based company is developing the AccuCinch Ventricular ...

Within the prior 24 months, I have had a financial relationship with a company producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients: Receive the the ...

The U.S. FDA has greenlighted Ancora Heart Inc.’s IDE request to conduct the Corcinch-HF pivotal clinical trial. The study is intended to demonstrate the safety and effectiveness of the Accucinch ...

The U.S. FDA has greenlighted Ancora Heart Inc.’s IDE request to conduct the Corcinch-HF pivotal clinical trial. The study is intended to demonstrate the safety and effectiveness of the Accucinch ...